Latozinemab is a medication being studied for its potential use in treating neurodegenerative diseases. This trial aims to provide continued access to this medication for participants who have already been involved in previous studies of latozinemab. The goal is to further understand its effects and benefits for individuals with these conditions.

Alzheimer’s Disease – A progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. It typically begins with mild memory lapses and confusion, gradually worsening over time. As the disease advances, individuals may experience difficulty with language, disorientation, mood swings, and impaired reasoning. In later stages, individuals may lose the ability to carry out daily activities and require full-time care. The exact cause is not fully understood, but it involves the buildup of amyloid plaques and tau tangles in the brain. It is the most common cause of dementia among older adults.

Parkinson’s Disease – A chronic and progressive movement disorder resulting from the loss of dopamine-producing brain cells. It primarily affects motor skills, leading to symptoms such as tremors, stiffness, slowness of movement, and balance problems. Non-motor symptoms can also occur, including sleep disturbances, mood changes, and cognitive impairment. The progression of symptoms varies among individuals, and the disease can lead to significant disability over time. The exact cause is unknown, but it involves both genetic and environmental factors. It is the second most common neurodegenerative disorder after Alzheimer’s disease.